The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 195-202

  Yu, Dihua ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ad5EIA; Gene therapy; HER 2 neu; Tumor suppressor

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; DRUG TARGETING; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW;

ADENOVIRUS E1A PROTEINS; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2;

EID: 0031816634     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006054421970     Document Type: Review

References (98)

1. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661-14665, 1994
2. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275, 1995
3. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997
4. Carraway KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti J, Vandelen RL, Cantley LC, Cerione RA: The erbB-3 gene product is a receptor for heregulin. J Biol Chem 269: 14303-14306, 1994
5. erbB-4. Nature 366: 473-475, 1993
6. Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898, 1993
7. neu levels in HER-2/neu transfected human lung cancer cells. J Natl Cancer Inst 87: 682-684, 1995
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, McGuire WL: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington, D.C.) 244: 707-712, 1989
10. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R: Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019-2023, 1987
11. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245, 1988
12. Zhang X, Silva E, Gershenson D, Hung M-C: Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. Oncogene 4: 985-989, 1989
13. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie P, Yin S, Bast JRC: Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990
14. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, Roth JA: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968-4971, 1989
15. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA, Kern JA: Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50: 421-425, 1990
16. Shi D, He G, Cao S, Pan W, Zhang H-Z, Yu D, Hung M-C: Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog 5: 213-218, 1992
17. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2: 283-287, 1988
18. Park J-B, Rhim JS, Park S-C, Kimm S-W, Kraus MH: Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 49: 6605-6609, 1989
19. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G Jr, Summerhayes IC: Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 4: 1233-1239, 1989
20. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL, Hung MC: Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clinical Cancer Res 3: 3-9, 1997
21. Yu D, Hung MC: Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996, 1991
22. Yusa K, Sugimoto Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T: Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. J Natl Cancer Inst 82: 1633-1636, 1990
23. Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, Yamamoto T: Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659). EMBO J 9: 181-190, 1990
24. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115, 1988
25. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931-936, 1989
26. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582, 1992
27. Yu D, Wang S-S, Dulski KM, Tsai C-M, Nicolson GL, Hung M-C: c-erbB-2/neu overexpression enhanced metastatic potential in human lung cancer cells. Cancer Res 54: 3260-3266, 1994
28. Tan M, Yao J, Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their tranformation abilities. Cancer Res 57: 1199-1205, 1997
29. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello T, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J, Ludwig IBCSG: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1044-1056, 1992
30. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575-4580, 1991
31. Pietras RJ, Fendly BM, Chazin VR, Pepram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene 9: 1829-1838, 1994
32. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ: p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758-3765, 1994
33. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: C-erbB-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994
34. Porter-Jordan K, Lippman ME: Overview of the biologic markers of breast cancer. Breast Cancer 8: 73-100, 1994
35. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1993
36. Yu D, Liu B, Tan M, Li J, Wang S-S, Hung M-C: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365, 1996
37. mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 16: 2087-2094, 1998
38. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER2/neu overexpression on chemotherapeutic drug setisitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547, 1997
39. Yu D, Hung M-C: HER-2/neu gene in human cancers. In: Freireich E, Stass SA (eds) Molecular Basis of Oncology, Blackwell Scientific Publications Inc., Cambridge, Vol, 131-162, 1995
40. Berk AJ: Adenovirus promoters and E1A transactivation. Ann Rev Genet 20: 45-79, 1986
41. Tooze J: DNA tumor viruses. In: (ed) Molecular Biology of Tumor Viruses, 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, Vol, 1981
42. Berger SL, Folk WR: Differential activation of RNA polymerase III-transcribed genes by the polyomavirus enhancer and the adenovirus E1A gene products. Nucl Acids Res 13: 1413-1428, 1985
43. Gaynor RB, Feldman LT, Berk AJ: Viral immediate early proteins activate transcription of class III genes. Science 230: 447-450, 1985
44. Hoeffler WK, Roeder RG: Enhancement of RNA polymerase III transcription by the E1A products of adenovirus. Cell 41: 955-963, 1985
45. Berk AJ, Lee F, Harrison T, Williams J, Sharp PA: A pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell 17: 1979
46. Ferguson B, Jones C, Richter J, Rosenberg M: Adenovirus E1A gene product expressed at high levels in Escherichia coli is functional. Science 224: 1343-1346, 1984
47. Jones N, Shenk T: An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 76: 1979
48. Nevins JR: Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 26: 213-220, 1981
49. Stein R, Ziff E: Hela cell β-tubulin gene transcription is stimulated by adenovirus 5 in parallel with viral early genes in an E1A-dependent mechanism. Mol Cell Biol 4: 2792-2801, 1984
50. Kao H-T, Nevins JR: Transcriptional activation and subsequent control of the human heat shock gene during adenovirus infection. Mol Cell Biol 3: 2058-2065, 1983
51. De Groot R, Foulkes N, Mulder M, Kruijer W, Sassone-Corsi P: Positive regulation of jun/AP-1 by E1A. Mol Cell Biol 11: 192-201, 1991
52. Sassone-Corsi P, Borrelli E: Promoter transactivation of protooncogenes c-fos and c-myc, but not c-Ha-ras, by products of adenovirus early region 1A. Proc Natl Acad Sci USA 84: 6430-6433, 1987
53. Borrelli E, Hen R, Chambon P: Adenovirus-2 E1A products repress enhancer-induced stimulation of transcription. Nature 312: 608-612, 1984
54. Hen R, Borrelli E, Chambon P: Repression of the immunoglobulin heavy chain enhancer by the adenovirus-2 E1A products. Science 230: 1391-1394, 1985
55. Velcich A, Ziff EB: Adenovirus E1A proteins repress transcription from the SV40 early promoter. Cell 40: 705-716, 1985
56. Velcich A, Kern FG, Basilico C, Ziff EB: Adenovirus E1A proteins repress expression from polyomavirus early and late promoters. Mol Cell Biol 6: 4019-4025, 1986
57. Stein R, Ziff EB: Repression of insulin gene expression by adenovirus type 5 E1A proteins. Mol Cell Biol 7: 1164-1170, 1987
58. Sogawa K, Handa H, Fujisawa-Sehara A, Hiromasa T, Yamane M, Fujii-Kuriyama Y: Repression of cytochrome P450c gene expression by cotransfection with adenovirus E1A DNA. Eur J Biochem 181: 539-544, 1989
59. Webster KA, Muscat GEO, Kedes L: Adenovirus E1A products suppress myogenic differentiation and inhibit transcription from muscle-specific promoters. Nature 332: 553-557, 1988
60. Timmers HTM, Van Dam H, Pronk GL, Van der Eb AJ: Adenovirus E1A represses transcription of the cellular JE gene. J Virol 63: 1470-1473, 1989
61. Van Dam H, Offringa R, Smits AMM, Bos JL, Jones NC, Van der Eb AJ: The repression of the growth factor-inducible genes JE, c-myc and stromelysin by adenovirus E1A is mediated by conserved region 1. Oncogene 4: 1207-1212, 1989
62. Friedman DJ, Ricciardi RP: Adenovirus type 12 E1A gene represses accumulation of MHC class I mRNAs at the level of transcription. Virology 165: 303-305, 1988
63. Berk AJ: Function of adenovirus E1A. Berk AJ (ed) Oxford University Press, Oxford, 1986
64. Branton PE, Bayley ST, Graham FL: Transformation by human adenoviruses. Biochem Biophys Acta 780: 67-94, 1985
65. Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, Van der Eb AJ: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305: 771-775, 1983
66. Ruley HE: Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304: 602-606, 1983
67. Byrd PJ, Grand RJA, Gallimore PH: Differential transformation of primary human embryo retinal cells by adenovirus E1A regions and combination of E1A(+) ras. Oncogene 2: 477-484, 1988
68. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602, 1983
69. Montell C, Courtois G, Eng C, Berk AJ: Complete transformation by adenovirus 2 requires both E1A proteins. Cell 36: 951-961, 1984
70. Moran E, Zerler B, Harrison TM, Mathews MB: Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes. Mol Cell Biol 6: 3470-3480, 1986
71. Shenk T, Flint J: Transcriptional and transforming activities of the adenovirus E1A proteins. Adv Cancer Res 57: 47-85, 1991
72. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E: Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129, 1988
73. Yu D, Suen T-C, Yan D-H, Chang LS, Hung M-C: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 87: 4499-4503, 1990
74. Yan D-H, Chang L-S, Hung M-C: Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1A gene products. Oncogene 6: 343-345, 1991
75. Yu D, Scorsone K, Hung M-C: Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 11: 1745-1750, 1991
76. Yu D, Hamada J-I, Zhang H, Nicolson GL, Hung M-C: Mechanisms of neu oncogene induced metastasis and abrogation of metastatic properties by the adenovirus 5 E1A gene products. Oncogene 7: 2263-2270, 1992
77. Yu D, Shi D, Scanlon M, Hung M-C: Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res 53: 5784-5790, 1993
78. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung M-C: Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/ neu. Oncogene 11: 1383-1388, 1995
79. Mulligan RC: The basic science of gene therapy. Science 260: 926-931, 1993
80. Zhang Y, Yu D, Xia W, Hung M-C: HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 10: 1947-1954, 1995
81. Zhang Y, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung M-C: The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14: 561-568, 1997
82. Chang JY, Xia W, Shao R, Hung MC: Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene 13: 1405-1412, 1996
83. Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung M: Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene 14: 1965-1971, 1997
84. Pozzatti R, McCormick M, Thompson MA, Khoury G: The E1A gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells. Mol Cell Biol 8: 2984-2988, 1988
85. Frisch SM: Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci USA 88: 9077-9081, 1991
86. Frisch SM, Dolter KE: Adenovirus E1A-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res 55: 5551-5555, 1995
87. van Groningen JJ, Cornelissen IM, van Muijen GN, Bloemers HP: Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with the adenovirus-5 E1A gene. Biochem Biophys Res Commun 225: 808-816, 1996
88. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E: The adenovirus E1A proteins induce apoptosis. which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89: 7742-7746, 1992
89. Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7: 535-545, 1993
90. Debbas M, White E: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7: 546-554, 1993
91. Teodoro JG, Shore GC, Branton PE: Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene 11: 467-174, 1995
92. Chen M-J, Holskin B, Strickler J, Gorniak J, Clark MA, Johnson PJ, Mitcho M, Shalloway D: Induction by E1A oncogene expression of cellular susceptibility to lysis by TNF. Nature 330: 581-584, 1987
93. Cook JL, May DL, Wilson BA, Holskin B, Chen M-J, Shalloway D, Walker TA: Role of tumor necrosis factor-a in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J Immunol 142: 4527-4534, 1989
94. Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg GI: Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 5: 75-83, 1990
95. Young KS, Weigel R, Hiebert S, Nevins JR: Adenovirus E1A-mediated negative control of genes activated during F9 differentiation. Mol Cell Biol 9: 3109-3113, 1989
96. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Can Inst 80: 200-204, 1988
97. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel ME: Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 E1A inhibition of experimental metastasis. Cancer Res 48: 6550-6554, 1988
98. Rosengard AM, Krutzsch HC, Shearn A, Biggs JR, Barker E, Margulies IMK, King CR, Liotta LA, Steeg PS: Reduced Nm23-Awd protein in tumor metastasis and aberrant Drosophila development. Nature 342: 177-180, 1989